Company Overview of H. Lee Moffitt Cancer Center & Research Institute
H. Lee Moffitt Cancer Center & Research Institute is a not for-profit institution that focuses on prevention and cure of cancer. The institution offers private patient rooms, blood and marrow transplant programs, outpatient treatment programs, patient care, research, and education services. Additionally, it publishes Today's Tomorrows, a community newsletter about cancer care, research, and education. H. Lee Moffitt was founded in 1986 and is based in Tampa, Florida.
10441 University Center Drive
Tampa, FL 33612
Founded in 1986
Key Executives for H. Lee Moffitt Cancer Center & Research Institute
Chief Executive Officer and Center Director
Executive Vice President Applied Science
Vice President of Public Relations and Marketing
Compensation as of Fiscal Year 2015.
H. Lee Moffitt Cancer Center & Research Institute Key Developments
Moffitt Cancer Center and Ignyta, Inc. Enter into Cancer Research Collaboration for RXDX-106
Nov 19 15
Moffitt Cancer Center and Ignyta, Inc. announced that they have entered into research collaboration relating to RXDX-106, Ignyta's small molecule, pseudo irreversible inhibitor of TYRO3, AXL, Mer (TAM) and cMET that is in late stage preclinical development. The collaboration, which will be conducted in the labs of Eric B. Haura, M.D., director of the Lung Cancer Center of Excellence and leader of the Chemical Biology and Molecular Medicine Program at Moffitt, will explore and develop novel protein based diagnostic assays that can assess RXDX-106 signaling activity in relevant solid tumors and associated tumor microenvironments.
H. Lee Moffitt Cancer Center & Research Institute Presents at 2015 BioFlorida Annual Conference, Oct-12-2015 11:40 AM
Sep 29 15
H. Lee Moffitt Cancer Center & Research Institute Presents at 2015 BioFlorida Annual Conference, Oct-12-2015 11:40 AM. Venue: Omni Orlando Resort at ChampionsGate, 1500 Masters Blvd, ChampionsGate, FL 33896, United States. Speakers: James J. Mule, Executive Vice President Applied Science.
Bristol-Myers Squibb Co. Partners with Moffitt Cancer Center to Advance Immuno-Oncology Research
Sep 25 15
Bristol-Myers Squibb Co. partnered with Moffitt Cancer Center to advance immuno-oncology research as part of Bristol-Myers' Immuno-Oncology Rare Population Malignancy (I-O RPM) program. Bristol-Myers and Moffitt will conduct various early phase clinical studies. The partnership will foster new Moffitt investigator-initiated studies for rare tumors and gives the faculty opportunity to educate research students about innovative clinical trials.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|